Using IHC, we next independently confirmed and validated biomarker specificity including CCND1 protein overexpression in gene fusion-positive ROs, MAPRE3, and ADGRF5 (also identified in the glycoproteomics analysis) expression in all RO subtypes (Figure 7D) and GPNMB in chRCC. This evidence concerns the gene ADGRF5 and chromophobe renal cell carcinoma.